Itolizumab

Itolizumab is a monoclonal antibody that selectively targets the CD6 antigen, which is expressed on the surface of T-cells, a type of white blood cell involved in the immune response. It is used for the treatment of chronic plaque psoriasis, a skin condition characterized by red, scaly patches, and inflammation.
The primary function of Itolizumab is to inhibit the activation and proliferation of T-cells, thereby reducing inflammation and improving the symptoms of psoriasis. It is typically administered through intravenous infusion, allowing the medication to directly target the affected areas of the skin.
Itolizumab has shown to be effective in reducing the severity of psoriasis, as well as improving the patient’s quality of life. Itolizumab is not a cure for psoriasis, and its effects may vary from person to person. Consult with a healthcare professional before starting treatment with Itolizumab to determine if it is the appropriate course of action for the individual patient.